摘要
目的:探讨肿瘤靶向药吉非替尼与中医药方剂益气除痰方联合治疗非小细胞肺癌(NSCLC)的临床疗效研究。方法:将80例非小细胞肺癌患者随机分为2组,每组各40例,治疗组用中医药益气除痰方联合吉非替尼治疗,对照组单用吉非替尼药物治疗。观察治疗前后2组NSCLC患者瘤体大小,血清肿瘤标志物(CEA、SCC),T淋巴细胞亚群参数,生存质量卡氏评分,不良反应发生率情况,血液生化等指标。结果:肿瘤体大小直径治疗前后比较,治疗组总稳定率高于对照组差异具有显著性(P<0.05);肿瘤标志物治疗前后比较,2组均能降低,但治疗组总体上优于对照组,差异具有显著性(P<0.05);T淋巴细胞亚群(CD3+、CD4+、CD8+)治疗前后比较,2组均能提高参数,但治疗组总体上优于对照组,差异具有显著性(P<0.05);生存质量卡氏评分、不良反应发生率治疗前后比较,治疗组明显低于对照组,差异有显著性(P<0.05)。结论:中医药益气除痰方联合吉非替尼治疗NSCLC较单用吉非替尼药物疗效好,并能有效改善患者生存质量,提高患者机体免疫力,减少不良反应发生率。
OBJECTIVE To investigate the clinical efficacy of gefitinib combined with traditional Chinese medicine yiqi zhitan fang in the treatment of non-small cell lung cancer(NSCLC).METHODS 80 patients with non-small cell lung cancer were randomly divided into two groups,40 patients in each group.The treatment group was treated with TCM yiqi and phlegm removing formula combined with gefitinib,while the control group was treated with gefitinib alone.Tumor size,serum tumor markers(CEA,SCC),Tlymphocyte subsets,quality of life cartesian score,incidence of adverse reactions,blood biochemistry and other indicators were observed in the two groups of NSCLC patients before and after treatment.RESULTS Compared with the control group,the total stabilization rate of tumor body size and diameter before and after treatment was significantly higher in the treatment group than in the control group(P<0.05);both groups could reduce tumor markers before and after treatment,but the treatment group was generally superior to the control group,the difference was significant(P<0.05);T lymphocyte subsets(CD3+,CD4+,CD8+)before and after treatment of both groups improved,but the treatment group was generally superior to the control group,the difference was significant(P<0.05);the quality of life Karnofsky score,the incidence of adverse reactions before and after treatment was significantly lower in the treatment group than in the control group,and the difference was significant(P<0.05).CONCLUSION Traditional Chinese medicine yiqi zhitanfang combined with gefitinib in the treatment of NSCLC is more effective than gefitinib alone,and can effectively improve the quality of life and the immunity of patients while reducing the incidence of adverse reactions.
作者
项琼
宋恩峰
莫郑波
林丽珠
XIANG Qiong;SONG En-feng;MO Zheng-bo;LIN Li-zhu(First Clinical College,Guangzhou University of Chinese Medicine,Guangdong Guangzhou 510504,China;Renmin Hospital of Wuhan University,Hubei Wuhan 430060,China)
出处
《中国医院药学杂志》
CAS
北大核心
2019年第24期2524-2528,共5页
Chinese Journal of Hospital Pharmacy
基金
广东省中医药管理局2018年卫生健康事业发展专项资金
中医药人才培养类项目(粤中医办函[2018]5号)
关键词
非小细胞肺癌(NSCLC)
中西医疗法
益气除痰方
吉非替尼
non-small cell lung cancer(NSCLC)
Chinese and western medicine
the prescription for benefiting qi and removing phlegm
gefitinib tablets
